Earnings

Eli Lilly Lowers FY2026 Adj EPS Guidance from $35.50-$36.50 to $35.00-$36.00 vs $34.04 Est; Raises FY2026 Sales Guidance from $85.000B-$87.000B to $91.000B-$92.000B vs $88.848B Est

Oct 29, 2026 · 06:49 AM ET· updated 1h ago

Eli Lilly (NYSE:LLY) lowers FY2026 Adj EPS guidance from $35.50-$36.50 to $35.00-$36.00 vs $34.04 analyst estimate. Raises FY2026 sales outlook from $85.000 billion-$87.000 billion to $91.000 billion-$92.000 billion vs

Why It Matters

Eli Lilly expects to sell way more stuff next year than before. But they expect to make slightly less money per share, which is still pretty good news overall.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

LLY1,346.00

+57.70 (+4.48%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.